Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Psychiatrists

Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
This is a potentially interesting alternative to current ADHD stimulant treatment. There is, I believe, existing literature on the efficacy of nicotine patches in the treatment of severe,otherwise intractable ADHD in children, which would seem to support these results. Of course, much work remains to...
Analysis of: Johnson & Johnson Presents Tapentadol Phase 3 Clinical Data at American Pain Society's Annual Meeting (www.investor.jnj.com)
Don't bother listening to the May 6 audio presentation, as it is a useless waste of time.  Just look at the pdf slide presentation, showing tapentadol IR to provide equivalent pain control to 10 or 15mg oxycodone, with reduced GI side effects, in treating acute bunionectomy pain and also arthritis...
Louis Sanfilippo, MD, President
Louis Sanfilippo, MD, President
LCS Group, LLC
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
Abbott’s Neuronal Nicotinic Receptor (NNR) partial agonist platform is an innovative target for ADHD and potentially other CNS disorders.  The Phase II data on ABT-089 suggests efficacy for adult ADHD with good safety/tolerability.  NNRs will not have the kind of effect size seen with stimulants...
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
NNR's are being heavily studied for several uses and are looking promising.
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents (newsroom.lilly.com)
Eli Lilly needs to find a compelling niche for Strattera since, in the treatment of ADHD, it is viewed as a less effective, though safer (because it cannot be abused), alternative to stimulants.
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
1. Effective treatment for ADHD 2. Well tolerated with few side effects 3. Help with smoking, a big problem in ADHD patients important 4. Advantage in not being Schedule II may be helpful
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents (newsroom.lilly.com)
1. Important new finding given safety concerns raised about this and other treatmetns 2. Nice to have data back up what has long been done clinically 3. Stimulants still first line and lack of active comparator trial
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
A novel neurochemical approach. Modulation of key neurotransmitter systems. Implications for a wide variety of psychiatric disorders.
Analysis of: Corcept Therapeutics Announces Commencement Of Next Phase 3 Study With CORLUX(R) For The Treatment Of Psychotic Depression (www.biospace.com)
This is an interesting development for treating psychotic depression, particularly, for dealing with the serious side of this illness, which is causing premature death and more illnesses associated with it. The information indicates that FDA is looking forward to make a quick approval due to the urgency...
Analysis of: NeuroSearch initiates pivotal Phase III programme with ACR16 for the treatment of Huntington’s disease (www.pipelinereview.com)
The news is showing a prospective development to treat Huntingdon's disease, which is  a major neurodegenrative disorder affecting a vast population groups across Europe and USA. As far as the recent treatment option is concerned, complete cure for Huntingdon's disease is not yet found, hence any...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next31 to 40 of 520

Analytics


Generated at 2009-01-09T13:00:20.343